TrialCompass™ TCL
Back to results
Not yet recruitingPriority 4 · Lower priorityNCT05343377

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This study is evaluating circulate free methylated EBV DNA as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 80 Years years
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

circulate free methylated EBV DNA (DIAGNOSTIC_TEST): Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

Drugs / treatments
circulate free methylated EBV DNA
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

NCT05343377

Status: Not yet recruiting | Priority: Lower

Plain-language summary

This study is evaluating circulate free methylated EBV DNA as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 80 Years years
  • Newly diagnosed, not yet treated

What's being tested

circulate free methylated EBV DNA (DIAGNOSTIC_TEST): Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

Drugs / treatments: circulate free methylated EBV DNA

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 72 patients

Primary endpoint: Assessing the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS in patients with newly diagnosed ENKTCL

Ages: 18 Years to 80 Years

Start date: 2022-06-01 | Est. completion: 2028-06-01

Locations

0 US sites · 1 total

Contact

wei xu | xuwei10000@hotmail.com | 025-68306034

Sponsor: The First Affiliated Hospital with Nanjing Medical University (OTHER)

Tags

ENKTL · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05343377

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.